TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy: A Randomized, Placebo-controlled Prospective Study
Brief Summary: Recent large randomized, placebo-controlled studies assessing the health effects of HT question the overall benefits of long term HT, especially with respect to cardiovascular disease. However, recently menopausal women with severe hot flushes were mostly excluded from these trials. This was unfortunate since vasomotor symptoms may reflect different vascular sensitivity to estrogen or its deficiency, and therefore, the vascular responses to HT in women with and without hot flushes can differ.

Aims of the present project are

1. to compare vascular, cardiac and sympathetic function in recently menopausal women with or without severe vasomotor symptoms
2. in a randomized placebo controlled clinical trial investigate vascular response to oral and trans-dermal HT.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Intervention Type: DRUG; Name: 17-b-estradiol; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol + medroxyprogeterone acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol hemihydrate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo pill + gel; Assigned to Arm(s): 1, 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bazedoxifene/Conjugate Estrogens (CE) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Raloxifene | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bazedoxifene/Conjugate Estrogens (CE); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C
C: Arm Label: Testosterone undecanoate; Type: EXPERIMENTAL; Interventions: Drug: Testosterone undecanoate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Testosterone undecanoate; Assigned to Arm(s): Testosterone undecanoate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Ospemifene; Type: EXPERIMENTAL; Interventions: Drug: Ospemifene | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ospemifene; Assigned to Arm(s): Ospemifene | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705
Brief Summary: The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.


Options:
A: Arm Label: PEP005 (Ingenol Mebutate) gel; Type: EXPERIMENTAL; Interventions: Drug: PEP005 (Ingenol Mebutate) gel, 0.015% | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle Gel | Intervention Type: DRUG; Name: PEP005 (Ingenol Mebutate) gel, 0.015%; Assigned to Arm(s): PEP005 (Ingenol Mebutate) gel | Intervention Type: DRUG; Name: Vehicle Gel; Assigned to Arm(s): Vehicle gel
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): 2
C: N/A
D: Arm Label: PEP005 (ingenol mebutate) Gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): PEP005 (ingenol mebutate) Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Vehicle gel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis
Brief Summary: The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.


Options:
A: Intervention Type: DRUG; Name: Glucosamine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chondroitin sulphate | Intervention Type: DRUG; Name: Chondroitin sulphate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Chondroitin 4&6 sulfate (Condrosulf); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chondroitin 4&6 sulfate (Condrosulf) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Chondroitin 4&6 sulfate (Condrosulf); Assigned to Arm(s): Chondroitin 4&6 sulfate (Condrosulf) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction - A Randomized, Double-blind, Placebo Controlled Trial (SCAMI)
Brief Summary: Autologous stem cells may improve myocardial regeneration after intracoronary administration in patients with acute myocardial infarction. The primary hypothesis of this prospective, placebo-controlled, double-blind trial is that the increase of ejection fraction determined by magnetic resonance imaging between baseline and 6 months follow-up is superior in active treated patients compared to patients receiving placebo. The study includes an integrated pilot phase of 40 patients for evaluation of left ventricular ejection fraction determined by cardiac magnetic resonance imaging. Based on the data of this analysis the final sample size will be calculated. The primary endpoint is the improvement in left ventricular ejection fraction with an assumed 2.5% higher improvement in the cell treated population compared to the placebo treated group.


Options:
A: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adult stem cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adult stem cells | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3, 4
C: Intervention Type: PROCEDURE; Name: intracoronary injection of bone marrow cells; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo suspension | Intervention Type: OTHER; Name: autologous stem cells; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo suspension; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rescue Antenatal Steroids and Lung Volumes in Preterm Infants
Brief Summary: One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
D: Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rescue Antenatal Steroids and Lung Volumes in Preterm Infants
Brief Summary: One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.


Options:
A: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Betamethasone | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rescue Antenatal Steroids and Lung Volumes in Preterm Infants
Brief Summary: One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.


Options:
A: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Betamethasone | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rescue Antenatal Steroids and Lung Volumes in Preterm Infants
Brief Summary: One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.


Options:
A: Intervention Type: DRUG; Name: Betamethasone sodium phos (drug); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Multiple vs. single courses of antenatalcorticosteroids; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rescue Antenatal Steroids and Lung Volumes in Preterm Infants
Brief Summary: One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: betamethasone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: Betamethasone sodium phos (drug); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Multiple vs. single courses of antenatalcorticosteroids; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: kühlender Effekt Der Eucerin pH5 Lotion Und Der Eucerin pH5 Lotion Mit Cooling Compound Bei Trockener, Juckender Haut
Brief Summary: Dry skin is a physiological condition and is characterized in contrast to greasy skin by roughness, desquamation and lack of brightness of the skin surface. Subjectively, feelings of tension, burning and itching can occur. The skin reacts more intensive on external and physical noxae. Dry skin is caused by a lack of moisture. This is most common during the winter months, when heating systems dry the air. Bathing with hot water, spending extended periods of time in the hot sun, and the skin's natural aging process also remove moisture and oils from the skin. It is diagnosed through clinical observation. People suffering from dry skin often desire to improve this condition for optical cosmetic reasons and due to the occasional feeling of tension. The aim of this investigation is to observe the improvement (or not) of dry itchy skin by a lotion containing a cooling compound


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: cooling compound (ph5 Eucerin) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: cooling compound (ph5 Eucerin) | Intervention Type: DEVICE; Name: cooling compound (ph5 Eucerin); Assigned to Arm(s): 1, 2
C: Arm Label: 0.25 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 1 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: 5 mg VPD-737; Type: EXPERIMENTAL; Interventions: Drug: VPD-737 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VPD-737; Assigned to Arm(s): 0.25 mg VPD-737, 1 mg VPD-737, 5 mg VPD-737 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients
Brief Summary: A randomised, prospective, cross over study will be done to determine whether the anticoagulation therapy with UFH or LMWH used for hemodialysis sessions modifies osteoprotegerin and RANKL plasma levels.


Options:
A: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin administration | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin administration | Intervention Type: DRUG; Name: Tinzaparin administration; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Heparin administration; Assigned to Arm(s): Heparin
B: Arm Label: ISIS-FXIRx Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ISIS-FXIRx Dose #2 | Arm Label: ISIS-FXIRx Dose 3; Type: EXPERIMENTAL; Interventions: Drug: ISIS-FXIRx Dose #3 | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: ISIS-FXIRx Dose #2; Assigned to Arm(s): ISIS-FXIRx Dose 2 | Intervention Type: DRUG; Name: ISIS-FXIRx Dose #3; Assigned to Arm(s): ISIS-FXIRx Dose 3 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
C: Arm Label: saline flushes; Type: PLACEBO_COMPARATOR; Interventions: Drug: two stage regional citrate | Arm Label: one stage regional citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: one stage regional citrate | Arm Label: two stage regional citrate; Type: EXPERIMENTAL; Interventions: Drug: two stage regional citrate, Drug: one stage regional citrate | Intervention Type: DRUG; Name: two stage regional citrate; Assigned to Arm(s): saline flushes, two stage regional citrate | Intervention Type: DRUG; Name: one stage regional citrate; Assigned to Arm(s): one stage regional citrate, two stage regional citrate
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: law molecular weigth heparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractioned heparin | Intervention Type: DRUG; Name: law molecular weigth heparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: unfractioned heparin; Assigned to Arm(s): B

Answer: D